Coronary artery disease (CAD) remains one of the leading causes of death worldwide. Yet one question continues to shape modern cardiovascular research: Why do some coronary plaques remain silent while others cause heart attacks?
Traditionally, cardiovascular risk assessment has focused on the degree of arterial narrowing and the presence of coronary artery calcification. However, advances in coronary CT angiography (CCTA) and AI-powered plaque analysis are revealing a more complex reality: the biological characteristics of a plaque may be just as important as the degree of stenosis.
Calcified plaque plays a critical role in cardiovascular risk assessment because it serves as a measurable marker of coronary atherosclerosis. The amount of calcium deposited within coronary arteries, expressed as the Coronary Artery Calcium (CAC) score, is strongly associated with both the presence of coronary artery disease and the likelihood of future cardiovascular events.
Evidence from the DISCHARGE study demonstrated a substantial increase in the prevalence of confirmed coronary artery disease, from 4.1% in patients with a CAC score of 0 to 76.1% in patients with a CAC score of 400 or greater. Similarly, patients with severe coronary calcification exhibited the highest risk of major adverse cardiovascular events (MACE) [1].
As a result, CAC scoring has become an important non-invasive tool for cardiovascular risk stratification, helping clinicians identify patients who may benefit from additional diagnostic evaluation or intensified preventive therapy.
However, calcification represents only one aspect of atherosclerotic disease. The absence of coronary calcium does not necessarily indicate the absence of plaque. Growing evidence suggests that patients with a CAC score of zero may still harbor clinically relevant non-calcified plaque, including lesions with features associated with increased cardiovascular risk [1].
Coronary atherosclerotic plaque development is a complex and progressive biological process characterized by dynamic changes in plaque composition and morphology. Early lesions are predominantly composed of lipid-rich, non-calcified tissue accompanied by inflammation within the arterial wall. These plaques may exhibit characteristics associated with vulnerability, making them susceptible to rupture and subsequent acute coronary syndromes.
As atherosclerosis progresses, repeated cycles of inflammation, tissue injury, and healing promote extracellular matrix remodeling and calcium deposition. Over time, non-calcified plaque may evolve into mixed plaque and eventually heavily calcified lesions.
Although calcification is generally considered a marker of advanced disease, both calcified and non-calcified components contribute to overall cardiovascular risk. Consequently, assessment of plaque composition and total plaque burden provides clinically relevant information beyond the evaluation of luminal stenosis alone.
For decades, cardiovascular imaging focused primarily on a single question:
How much does the plaque narrow the artery?
Today, research increasingly suggests that a more relevant question may be:
How dangerous is the plaque itself?
Many myocardial infarctions originate from lesions that are not severely obstructive. Instead, the biological properties of the plaque often determine its likelihood of causing future cardiovascular events.
Historically, the assessment of coronary artery disease focused primarily on the identification and quantification of luminal stenosis. However, growing evidence suggests that plaque burden, plaque composition, and morphological characteristics provide prognostic information beyond vessel narrowing alone.
This evolution reflects a broader shift in cardiovascular medicine. Rather than evaluating only whether blood flow is compromised, clinicians are increasingly interested in understanding the biological behavior of atherosclerotic disease.
Advanced coronary CT imaging now enables detailed assessment of plaque volume, composition, and high-risk plaque features, supporting a more comprehensive approach to cardiovascular risk assessment and personalized patient management.
Recent evidence continues to strengthen the role of quantitative plaque analysis in coronary artery disease assessment.
A study presented at ESC 2026 demonstrated that AI-based quantitative coronary CT analysis (AI-QCT) provides significant long-term prognostic value in patients with suspected coronary artery disease. In a cohort of 1,385 patients followed for a median of 7.1 years, higher AI-quantified plaque burden, expressed as percent atheroma volume (PAV), was independently associated with major cardiovascular events at 3, 6, and 9 years [2].
Additional findings presented at ESC Congress 2026 showed that automated deep-learning quantification of total plaque volume improved prediction of first coronary events beyond traditional cardiovascular risk scores, coronary calcium scoring, and conventional CCTA findings [3].
Collectively, these findings support the growing role of quantitative plaque analysis as a powerful imaging biomarker for long-term cardiovascular risk assessment and preventive cardiology.
Despite growing evidence linking vulnerable plaque characteristics to future cardiovascular events, comprehensive plaque biology assessment remains difficult to implement in routine clinical practice.
Historically, treatment guidelines, reimbursement models, and clinical workflows have been centered on the detection of flow-limiting stenosis. Consequently, stenosis continues to dominate decision-making in many healthcare systems.
Comprehensive plaque characterization presents additional practical challenges. Assessment of low-attenuation plaque, plaque burden, remodeling, and plaque composition traditionally requires specialized expertise and substantial interpretation time. Manual plaque quantification may require extensive post-processing and is susceptible to inter-observer variability.
Until recently, these limitations prevented widespread adoption of plaque-focused cardiovascular assessment.
Artificial intelligence is transforming coronary CT angiography from a tool primarily focused on stenosis detection into a comprehensive platform for plaque characterization and cardiovascular risk assessment.
AI-guided quantitative plaque analysis enables automated and reproducible evaluation of:
Importantly, AI significantly reduces analysis time while improving consistency and scalability.
Research has shown that AI-guided plaque analysis can achieve strong agreement with expert human readers and provide clinically meaningful prognostic information beyond traditional risk assessment methods [4].
The transition from stenosis assessment to comprehensive plaque characterization aligns closely with the mission of Brighter Imaging.
Brighter Imaging leverages advanced AI technologies to transform routine CCTA examinations into actionable cardiovascular insights. By enabling automated assessment of coronary stenosis, plaque burden, plaque composition, and disease progression, the platform supports a more comprehensive evaluation of coronary artery disease.
As evidence increasingly highlights the importance of vulnerable plaque biology, AI-powered solutions such as Brighter Imaging can help make advanced plaque analysis more scalable, reproducible, and clinically accessible, supporting earlier identification of high-risk patients and more personalized preventive care.
The most clinically significant plaque is not necessarily the largest or the one causing the greatest degree of luminal stenosis.
Growing evidence indicates that plaque burden, plaque composition, and vulnerable plaque characteristics are key determinants of cardiovascular risk. As cardiovascular imaging continues to evolve, the focus is gradually shifting from identifying narrowed arteries to understanding the biological behavior of atherosclerotic disease.
Through AI-powered CCTA analysis and quantitative plaque assessment, clinicians can obtain a more comprehensive view of coronary artery disease, enabling earlier detection of high-risk plaque features, more accurate monitoring of disease progression, and a transition toward a truly preventive model of cardiovascular care. Platforms such as Brighter Imaging are helping accelerate this transformation by bringing advanced coronary plaque analysis into everyday clinical workflows.
REFERENCES:
[1] Graylight Imaging. Coronary artery calcification and… beyond calcification. https://graylight-imaging.com/blog/coronary-artery-calcification-and-beyond-calcification/
[3] ESC Congress 2026 presentation on automated deep-learning quantification of coronary plaque volume demonstrating incremental predictive value over traditional risk factors, CAC scoring, and conventional CCTA findings. https://www.acc.org/latest-in-cardiology/articles/2026/08/24/12/30/sat-jacc-studies-esc-2026
[4] Basunia A, Jagasia D, Jamal F. AI-Guided Coronary Plaque Analysis from Coronary CTA: An Emerging Paradigm for Personalized Preventive Cardiology. Applied Radiology, 2026. https://www.appliedradiology.com/articles/ai-guided-coronary-plaque-analysis-from-coronary-cta-an-emerging-paradigm-for-personalized-preventive-cardiology